Icariin decreases both APP and Aβ levels and increases neurogenesis in the brain of Tg2576 mice

Li, F.; Dong, Hongxin; Gong, Qihai; Wu, Qin; Jin, Feng; Shi, Jingshan

doi:10.1016/j.neuroscience.2015.06.010

Cited by 46 publications

(26 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous studies have documented that abnormal protein expression of APP and BACE1 could facilitate Aβ production in AD mice and our experiment results agreed with this (Jin et al, 2014; Li et al, 2015; Du et al, 2016). BACE1 is a type I transmembrane aspartic protease that is responsible for cleaving APP at the β-secretase cleavage site to generate sAPPβ and formation of a 99-amino-acid-long C-terminal membrane-bound fragment (C99).…”

Section: Discussionsupporting

confidence: 92%

Icariside II Effectively Reduces Spatial Learning and Memory Impairments in Alzheimer’s Disease Model Mice Targeting Beta-Amyloid Production

et al. 2017

View full text Add to dashboard Cite

Icariside II (ICS II) is a broad-spectrum anti-cancer natural compound extracted from Herba Epimedii Maxim. Recently, the role of ICS II has been investigated in central nervous system, especially have a neuroprotective effect in Alzheimer’s disease (AD). In this study, we attempted to investigate the effects of ICS II, on cognitive deficits and beta-amyloid (Aβ) production in APPswe/PS1dE9 (APP/PS1) double transgenic mice. It was found that chronic ICS II administrated not only effectively ameliorated cognitive function deficits, but also inhibited neuronal degeneration and reduced the formation of plaque burden. ICS II significantly suppressed Aβ production via promoting non-amyloidogenic APP cleavage process by up-regulating a disintegrin and metalloproteinase domain 10 (ADAM10) expression, inhibited amyloidogenic APP processing pathway by down-regulating amyloid precursor protein (APP) and β-site amyloid precursor protein cleavage enzyme 1 (BACE1) expression in APP/PS1 transgenic mice. Meanwhile, ICS II attenuated peroxisome proliferator-activated receptor-γ (PPARγ) degradation as well as inhibition of eukaryotic initiation factor α phosphorylation (p-eIF2α) and PKR endoplasmic reticulum regulating kinase phosphorylation (p-PERK). Moreover, phosphodiesterase type 5 inhibitors (PDE5-Is) have recently emerged as a possible therapeutic target for cognitive enhancement via inhibiting Aβ levels, and we also found that ICS II markedly decreased phosphodiesterase-5A (PDE5A) expression. In conclusion, the present study demonstrates that ICS II could attenuate spatial learning and memory impairments in APP/PS1 transgenic mice. This protection appears to be due to the increased ADAM10 expression and decreased expression of both APP and BACE1, resulting in inhibition of Aβ production in the hippocampus and cortex. Inhibition of PPARγ degradation and PERK/eIF2α phosphorylation are involved in the course, therefore suggesting that ICS II might be a promising potential compound for the treatment of AD.

show abstract

Section: Discussionsupporting

confidence: 92%

Icariside II Effectively Reduces Spatial Learning and Memory Impairments in Alzheimer’s Disease Model Mice Targeting Beta-Amyloid Production

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Cell proliferation (Li et al, 2015;Taniuchi et al, 2007), survival (Crews et al, 2010;Hamilton et al, 2010) and neuronal differentiation (Shruster and Offen, 2014;Valero et al, 2011) have all been observed to be reduced in mouse models of AD. Moreover, changes in neuronal morphology have also been reported in some studies (Biscaro et al, 2012;Valero et al, 2011).…”

Section: Alterations In Hippocampal Neurogenesis In Ad Mouse Modelsmentioning

confidence: 99%

“…Indeed, several studies have assessed cognitive function simultaneously with hippocampal neurogenesis. Deficits in spatial memory (Ben-Menachem-Zidon et al, 2014;Choi et al, 2014b;Iascone et al, 2013;Tapia-Rojas et al, 2016;Valero et al, 2011), spontaneous alternation (Li et al, 2015), contextual memory (Ben- MenachemZidon et al, 2014;Imbimbo et al, 2010) and recognition memory (Biscaro et al, 2012;Blanchard et al, 2010) have all been observed to occur alongside reductions in hippocampal neurogenesis. Interestingly, Yu et al (2009) report that nine month old APP + PS-1 mice are impaired in the MWM task and have increased hippocampal neurogenesis.…”

Section: Alterations In Hippocampal Neurogenesis In Ad Mouse Modelsmentioning

confidence: 99%

Exercise as a pro-cognitive, pro-neurogenic and anti-inflammatory intervention in transgenic mouse models of Alzheimer’s disease

Ryan

Kelly

2016

Ageing Research Reviews

View full text Add to dashboard Cite

a b s t r a c tIt is now well established, at least in animal models, that exercise elicits potent pro-cognitive and proneurogenic effects. Alzheimer's disease (AD) is one of the leading causes of dementia and represents one of the greatest burdens on healthcare systems worldwide, with no effective treatment for the disease to date. Exercise presents a promising non-pharmacological option to potentially delay the onset of or slow down the progression of AD. Exercise interventions in mouse models of AD have been explored and have been found to reduce amyloid pathology and improve cognitive function. More recent studies have expanded the research question by investigating potential pro-neurogenic and anti-inflammatory effects of exercise. In this review we summarise studies that have examined exercise-mediated effects on AD pathology, cognitive function, hippocampal neurogenesis and neuroinflammation in transgenic mouse models of AD. Furthermore, we attempt to identify the optimum exercise conditions required to elicit the greatest benefits, taking into account age and pathology of the model, as well as type and duration of exercise.© 2016 Elsevier B.V. All rights reserved. Please cite this article in press as: Ryan, S.M., Kelly, Á.M., Exercise as a pro-cognitive, pro-neurogenic and anti-inflammatory intervention in transgenic mouse models of Alzheimer's disease. Ageing Res. Rev. (2016), http://dx

show abstract

“…Therefore, in the treatment of AD, multicomponent and multitarget drugs, such as TCM, may be advantageous over single‐target drugs . To promote the expression of endogenous NTFs, TCM plays therapeutic roles on depression , cerebral ischemia , Parkinson's disease , spinal cord injury , diabetic encephalopathy , autoimmune encephalomyelitis , and AD and shows tremendous potential value in the treatment of nervous system disease. Although various preclinical reports have identified the effects of TCMs on AD, clinical evidences are still insufficient .…”

Section: Resultsmentioning

confidence: 99%

Potential therapeutic action of natural products from traditional Chinese medicine on Alzheimer's disease animal models targeting neurotrophic factors

Wei

2016

Fundamemntal Clinical Pharma

View full text Add to dashboard Cite

Alzheimer's disease (AD) is a neurodegenerative disorder in which the death of brain cells leads to memory loss and cognitive decline. To reduce the death rate and improve the biological activity of neurocytes, neurotrophic factors (NTFs) exhibit therapeutic effect on AD. However, therapeutic application of exogenous NTFs in treatment of AD is largely limited due to short half-life, poor stability, etc. Various extracts of traditional Chinese medicine (TCM) have been shown to exhibit therapeutic effects on AD, and some of these effects are associated with regulation on the expression of nerve growth factor, brain-derived neurotrophic factor (BDNF), and glial cell line-derived neurotrophic factor (GDNF) and their associated receptors. This article reviews the progress on promotion of Panax ginseng, Rehmannia glutinosa Libosch., Epimedium, Polygala tenuifolia Willd, and seven other TCMs on secretion of NTFs during AD, with a view to preparation development and clinical application of these TCMs on AD.

show abstract

Icariin decreases both APP and Aβ levels and increases neurogenesis in the brain of Tg2576 mice

Cited by 46 publications

References 46 publications

Icariside II Effectively Reduces Spatial Learning and Memory Impairments in Alzheimer’s Disease Model Mice Targeting Beta-Amyloid Production

Icariside II Effectively Reduces Spatial Learning and Memory Impairments in Alzheimer’s Disease Model Mice Targeting Beta-Amyloid Production

Exercise as a pro-cognitive, pro-neurogenic and anti-inflammatory intervention in transgenic mouse models of Alzheimer’s disease

Potential therapeutic action of natural products from traditional Chinese medicine on Alzheimer's disease animal models targeting neurotrophic factors

Contact Info

Product

Resources

About